Articles tagged with Hormone Therapy
A study found gene polymorphisms in hormone metabolism and growth factor pathways associated with breast density, which increases breast cancer risk. Variants in genes like PRL, TNF, and SULT1A1/2 were linked to breast density in both hormone therapy users and non-users.
The US Preventive Services Task Force recommends against the use of estrogen and progestin for chronic disease prevention in postmenopausal women. Hormone replacement therapies may reduce fracture risk but increase risk for stroke, thromboembolic events, and urinary incontinence. The recommendations aim to balance benefits with risks.
A multi-center team of scientists will focus on identifying causes of resistance in advanced prostate cancer and tailoring therapy for patients. The goal is to revolutionize treatment through personalized medicine, sparing unnecessary treatment.
Researchers found that women with multiple sclerosis who undergo assisted reproduction technology are at risk for increased disease activity. Sex hormones and reproductive hormones contribute to the regulation of immune responses in autoimmune diseases like MS.
The new guidelines provide updated recommendations for diagnosing and treating hypothyroidism, a complex condition affecting millions worldwide. The guidelines aim to address issues with inappropriate thyroid hormone administration and suboptimal dosing.
USDA scientists developed a hormone treatment to strengthen male Mexican fruit flies, allowing them to compete with wild-type males for female mates more effectively. The therapy uses methoprene and hydrolyzed protein supplements, resulting in faster maturation and improved mating success.
Researchers found that tamoxifen effectively suppresses gynecomastia and breast pain in men with prostate cancer. Treatment with tamoxifen was more successful than with aromatase inhibitors or radiotherapy in reducing breast symptoms.
A randomized clinical trial found that treatment with growth hormone-releasing hormone improved cognitive function in both healthy older adults and those with mild cognitive impairment. The study also showed increased insulin-like growth factor 1 levels, which may play a role in brain health.
Researchers found that paxillin regulates cell growth even in hormone therapy-resistant tumors, providing a new treatment target for advanced prostate cancer. The discovery could potentially lead to the development of targeted therapies that selectively attack cancer cells while leaving healthy cells intact.
Research published in PLOS ONE reveals a significant association between menopausal hormone therapy and high blood pressure in postmenopausal women. Longer use of hormone therapy was found to increase the odds of developing high blood pressure, although this risk decreased with age.
A national survey of physicians found that patient fears and misinformation are major barriers to treating menopausal symptoms. The Endocrine Society has developed the Menopause Map, an online tool to guide women through treatment options and assess individual risk factors.
A new study found that long-term treatment with estrogen and MPA increased levels of a protein marker for synapses in the prefrontal cortex of aged rats. This contradicts previous research on human hormone therapy, which linked hormone replacement to an increased risk of stroke and dementia.
15 top medical organizations have issued a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. The statement concludes that hormone therapy is still an acceptable treatment for menopausal symptoms and has been endorsed by leading organizations in women's health.
A study published in The Journal of Nuclear Medicine found that imaging progesterone receptor (PR) status can identify responders and nonresponders to endocrine therapy in early stages. PR imaging with F-18-FFNP PET may help distinguish between patients who will benefit from hormone-based therapies.
A new study presented at The Endocrine Society's 94th Annual Meeting has found that monitored vitamin D therapy is safe for patients with primary hyperparathyroidism and vitamin D deficiency. Vitamin D treatment helped lower parathyroid hormone levels, but did not raise calcium blood levels in patients.
Researchers found that patients treated with hormonal therapy and rehabilitation outperformed those with rehab alone on functioning and reasoning tests. Relaxin has been shown to have a tremendous promise in treating and preventing heart and blood vessel diseases.
A new study finds that testosterone-replacement therapy significantly improved symptoms of metabolic syndrome associated with testosterone deficiency in men. Symptoms improved across all three components of obesity, including waist circumference, weight, and body-mass index.
A new study found that long-term testosterone treatment resulted in significant weight loss, with an average of 36 pounds lost over two years. Men also experienced a reduction in waist size, shedding nearly 3.5 inches around their midsection.
A new study presents promising results for an investigational parathyroid hormone replacement in treating hypoparathyroidism, a rare disorder marked by low calcium and high phosphate levels. The treatment effectively regulated calcium levels and reduced the need for additional vitamin D in over half of patients.
Weekly fertility hormone injections are as safe and effective as standard daily injections in increasing pregnancies and minimizing serious side effects. Women undergoing fertility treatment may prefer weekly injections for their patient-friendly nature.
Dr. Rowan Chlebowski, a leading breast cancer researcher at LA BioMed, has been recognized for his significant contributions to cancer prevention and control through the ASCO-American Cancer Society Award and Lecture. His work on clinical trials and lifestyle interventions has reduced breast cancer recurrence and incidence.
A study by the Society of Nuclear Medicine found that most patients with differentiated thyroid cancer have excellent survival rates, similar to those without the disease. The majority of patients with early-stage thyroid cancer can live a long and healthy life, thanks to advancements in diagnostic and therapeutic strategies.
A seventeen-year study led by SWOG found that intermittent hormone therapy for metastatic prostate cancer is inferior to continuous therapy, with overall survival times shorter for many patients. The treatment approach was also shown to have varying effects on different disease stages.
The Women's Health Initiative (WHI) Hormone Therapy Trial radically changed the practice of women's health, showing that younger women have better outcomes on hormone therapy than older women. The study highlights the importance of individualized care for women and underscores the need to understand different types of hormone therapy.
The Women's Health Initiative has revealed that hormones produce a mix of risks and benefits for postmenopausal women. The trial found that HT varies with age, being safer when started soon after menopause.
The American College of Physicians Task Force recommends updating hormone therapy guidelines due to significant adverse events. Exercise and vitamin D supplementation are effective at reducing falls, but multifactorial risk assessment is not recommended for all elderly patients.
A cancer vaccine targeting MUC1 glycoprotein significantly increased survival when combined with the drug letrozole in mice. The findings suggest a promising new approach to combating cancer using immunotherapy.
Researchers have made significant breakthroughs in understanding the biological differences between individual breast cancers, highlighting the importance of biomarkers in identifying new targets for therapy. Studies also explored the mechanisms behind endocrine resistance and proposed a new approach to predicting response to treatment.
Researchers at Fox Chase Cancer Center have identified two proteins that could restore treatment sensitivity to hormone-resistant breast cancer cells. These proteins may help develop a new therapy combining estrogen and interferon-alpha, offering more treatment options for patients with resistant disease.
A new mathematical model predicts optimal treatment length for prostate cancer patients to delay resistance, allowing clinicians to tailor therapy effectively. Intermittent androgen suppression therapy reduces side effects and improves patient outcomes.
A national clinical trial found that preoperative aromatase inhibitors enabled postmenopausal women with estrogen receptor-positive breast cancer to have lumpectomy instead of mastectomy. The treatment increased the likelihood of breast-conserving surgery, sparing women's breasts.
A recent review of large prospective cohort studies and WHI trials found that estrogen plus progestin increases breast cancer risk, while estrogen alone decreases risk in women with a previous hysterectomy. The study proposes that mammography screening differences may explain the observed effects.
A new study published in The Lancet Oncology found that estrogen-only form of menopausal hormone therapy continues to protect women from breast cancer, with a 23% reduced incidence and 63% lower mortality rate compared to placebo. The research followed over 7,500 women for nearly 12 years.
Women who used estrogen-only hormone replacement therapy (HRT) are less likely to develop breast cancer and die from the disease compared to those who never used HRT. The study, based on data from over 7,500 women, found a 23% reduction in breast cancer incidence and a 63% reduction in deaths from the disease.
Researchers report growing success in combining therapeutic cancer vaccines with conventional chemotherapy, stimulating the immune system to destroy cancer cells. The first FDA-approved cancer vaccine is for metastatic prostate cancer, and several other strategies are being tested for various types of cancer.
A new study published in The Lancet Oncology shows that cognitive behavioural therapy (CBT) significantly reduces hot flushes and night sweats in women after breast cancer treatment. CBT improves symptoms by 46-52% compared to usual care, with sustained benefits at 26 weeks.
Researchers have discovered a new way to enhance trastuzumab treatment in HER2-positive breast cancer patients by stimulating natural killer cells. Additionally, the activation of FoxO1 has been linked to the development of diabetic cardiomyopathy, offering a promising therapeutic target. Leptin's direct action on POMC neurons may also...
Researchers use molecular imaging to improve diagnosis and treatment decisions for estrogen-receptor positive breast cancer patients, detecting bone metastases and predicting therapy response. PET imaging with 18F-FES and 18F-FDG improves diagnostic information and prompts changes in treatment for 88% and 48% of subjects respectively.
Researchers found that oxytocin administration enhanced prosocial choices in rhesus macaques, making them pay attention to each other and choose to give juice to a neighbor. The hormone also increased gaze duration when choosing to reward another monkey, suggesting improved social skills.
A study by McMaster researchers found consistent evidence that hormone replacement therapy is associated with an increased risk of breast cancer globally. The research suggests that decreased HRT use after the WHI trial led to a decline in breast cancer incidence in many countries.
Researchers found that combining everolimus and exemestane significantly improved progression-free survival by 4.2 months, with a clinical benefit rate of 50.5% in the combination arm. The study suggests a new approach for treating hormone-resistant breast cancer, which may change treatment practices.
Researchers confirm zoledronic acid's continued effectiveness in reducing breast cancer recurrences and improving survivorship rates among premenopausal women with estrogen receptor-positive breast cancer. The study found a 28% reduced risk for recurrence and a 36% reduction in mortality risk, with no toxic side effects.
Androgen suppression therapy used to treat advanced prostate cancer may significantly increase the risk of heart disease and stroke, say specialists. This risk is often overlooked in standard management of the disease.
A new meta-analysis of randomized studies involving 4,141 prostate cancer patients found no difference in cardiovascular deaths between those receiving androgen deprivation therapy (ADT) and those who didn't. The study suggests that ADT may not increase the risk of fatal heart attacks for men without a history of heart disease.
A significant number of women with breast cancer are not receiving guideline-recommended adjuvant treatment. The research found that socioeconomic factors such as poverty, insurance status, and education level significantly contribute to this disparity. Women from high-poverty areas were less likely to receive guideline therapy, highli...
Researchers at Addex Pharmaceuticals have discovered a novel interaction between GLP-1 and GIP receptors, which has the potential to trigger new therapies for Type 2 diabetes. The discovery was made possible by the company's allosteric modulation platform and could lead to the development of orally available small molecule treatments.
Researchers identify a new way to boost the aged immune response to flu viruses by inhibiting PGD2. They also discover that targeting BRAF in thyroid cancers could restore the efficacy of RAI therapy. Additionally, exploring EGFR as a therapeutic target for Cushing disease may provide new treatment options.
A new mathematical model predicts individual patient responses to therapy and identifies optimal treatments for advanced prostate cancer. The model incorporates personalized data, including tumor cell characteristics, to provide more accurate treatment decisions.
A recent study found that women taking combination estrogen and progestin menopausal hormone therapy are at a greater risk of developing breast cancer if they experience new onset breast tenderness. In contrast, women on estrogen alone without breast tenderness did not have an increased risk of breast cancer.
Researchers found that introducing a novel histone deacetylase inhibitor can reverse tumor's survival strategy and stop resistance, leading to higher cell death rates. This approach may prevent hormone therapy resistance in patients with estrogen receptor-positive breast cancer.
Men with locally advanced or high-risk prostate cancer who receive combined radiation and hormone therapy live longer and are less likely to die from their disease. The treatment improved overall survival by 23% and disease-specific survival by 43% compared to hormone therapy alone.
Research shows that repeated administrations of radionuclide therapy with 188Re-HEDP improve overall survival rates, reducing pain in prostate cancer patients with hormone-refractory bone metastases. The study found significant increases in post-treatment survival for patients receiving two or three therapies.
Scientists at UH outline a new strategy for developing drugs to treat cancer, multiple sclerosis, Alzheimer's, and cardiovascular diseases. They identify estrogen receptor beta (ERβ) as a potential target for these treatments.
Post-menopausal women experiencing new onset breast tenderness after starting combination hormone therapy may have an increased risk of breast cancer compared to those without breast tenderness. Higher breast density is associated with a higher risk of breast cancer, with extremely dense breasts posing a four to six times higher risk.
Researchers have identified estrogen receptors in specific brain areas that influence metabolism, weight gain, and fertility. Deleting these receptors from mice resulted in significant weight gain and metabolic changes.
Researchers at the University of Houston have discovered that estradiol, a naturally occurring estrogen hormone, plays a prominent role in regulating body functions in both females and males. The study found that an imbalance of estradiol levels can result in metabolic diseases, including diabetes, obesity, and cardiovascular disease.
Researchers found a positive association between HRT use and asthma hospitalizations, with women taking the drug for over 10 years facing a higher risk. The study suggests that women on HRT may need to consider stopping hormone therapy if they experience severe asthma symptoms.
A 12-year update of the Breast International Group 1-98 trial shows that letrozole reduces the risk of breast cancer relapse by 18% and death by 21% compared to tamoxifen after surgery. The study provides long-term reassurance on the efficacy of aromatase inhibitors in preventing breast cancer recurrence.
A phase III clinical trial shows that abiraterone acetate significantly improves fatigue in men with metastatic castration-resistant prostate cancer. The treatment also delays the progression of fatigue and has a potential survival benefit.
A phase III clinical trial has shown that combining everolimus and exemestane significantly improves progression-free survival for women with advanced breast cancer resistant to hormonal therapy. The combination treatment resulted in an improved survival of nearly seven months compared to women treated with only exemestane.